Davis Polk & Wardwell is advising Genetron Holdings Limited and, separately, the special committee of the board of directors of Genetron on the transaction, Skadden, Arps,...
Genetron Health’s $126 Million Merger Agreement with Genetron New Co Limited
Gracell Biotechnologies’ $150 Million Private Placement Financing
Cooley advised Gracell Biotechnologies; and Davis Polk & Wardwell advised the placement agents on the deal. Gracell Biotechnologies Inc. (Nasdaq: GRCL) announced that it has entered into a...
Laekna’s HK$791 Million Initial Public Offering
Davis Polk, Jingtian & Gongcheng and Harney Westwood advised Laekna, while Cooley and Commerce & Finance Law Offices advised the sole sponsor and the underwriters. Laekna,...
Laekna Therapeutics’ $61 Million Series D Financing
Davis Polk advised Laekna Therapeutics in the transaction. Laekna Therapeutics completed its $61 million Series D financing led by CS Capital with support from Worldstar, and Infinity...
CANbridge Pharmaceuticals Inc.’s HK$604 Million IPO
Harneys, alongside Davis Polk & Wardwell and King & Wood Mallesons, acted as Cayman Islands counsel to CANbridge Pharmaceuticals Inc. Kirkland & Ellis and Tian Yuan...
MicroTech Medical’s US$249 Million Initial Public Offering
Davis Polk advised MicroTech Medical, while Clifford Chance has advised the joint sponsors involved in the transaction. The Hangzhou-based firm offers diabetes therapy and manufactures medical...
Broncus Holding’s HK$1.55 Billion Initial Public Offering
Davis Polk, Gleiss Lutz and Maples and Calder advised Broncus Holding Corporation, while Dentons Hong Kong advised Goldman Sachs and Haitong International Capital in the transaction....
Kindstar Globalgene Technology’s US$285.2 Million IPO
S&C acted as Hong Kong and U.S. counsel to the joint sponsors and underwriters, including Goldman Sachs, CICC and Credit Suisse. Davis Polk advised Kindstar Globalgene...
Zylox-Tonbridge’s US$330 Million IPO and Listing on the Hong Kong Stock Exchange
Davis Polk advised Zylox-Tonbridge Medical Technology Co., Ltd., while Clifford Chance has advised Morgan Stanley, CLSA and other underwriters. Grandall Advised Zylox-Tonbridge. JunHe advised Zylox-Tonbridge. The...
HUTCHMED’s HK$ 4.17 Billion Initial Public Offering
DLA Piper advised HUTCHMED, while Linklaters and Davis Polk advised the joint sponsors and underwriters on the global offering and listing of HUTCHMED (China) Limited on...
CARsgen Therapeutics Holdings Limited’s Listing on the Stock Exchange of Hong Kong
Davis Polk and Maples and Calder advised CARsgen Therapeutics Holdings Limited, while Herbert Smith Freehills and Zhong Lun advised Goldman Sachs and UBS on the deal....
Zai Lab’s $857.5 Million Shares Offering
Davis Polk advised Zai Lab Limited in the deal, while Simpson Thacher represented the underwriters. Zai Lab Limited executed its offering of 5,492,400 American depositary shares,...